Form 4: Kymera CFO Jacobs Receives Equity, Sells Shares for Tax

Kymera Therapeutics' CFO, Bruce N. Jacobs, was granted restricted stock units and stock options, while also selling shares to cover tax withholding obligations.

Summary

• Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, Inc. (KYMR), reported equity transactions.
• On March 2, 2026, Jacobs acquired 17,650 restricted stock units (RSUs) at a price of $0. These RSUs will vest in four equal annual installments starting March 2, 2026, contingent on continued employment.
• Also on March 2, 2026, Jacobs acquired 35,300 stock options with an exercise price of $90.1. These options will vest in 48 equal monthly installments starting March 2, 2026, contingent on continued employment.
• Jacobs sold a total of 9,000 shares of common stock on March 2, 2026, and March 4, 2026, to cover tax withholding obligations related to the vesting of RSUs.
• The sales occurred at weighted average prices ranging from $83.9965 to $89.6574 per share.
• Following these transactions, Jacobs beneficially owns 232,588 shares of common stock and 35,300 stock options.
• All sales were automatic and not at the discretion of the reporting person, conducted under a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects a significant equity grant to a key executive, aligning his interests with long-term company performance, while the sales are routine tax-related transactions under a 10b5-1 plan.

Positives

• The Chief Financial Officer received a significant grant of 17,650 restricted stock units and 35,300 stock options, indicating continued long-term incentive and alignment with shareholder interests.
• The equity grants are subject to vesting over several years, reinforcing management's commitment to the company's long-term performance.

Negatives

• The sale of 9,000 shares of common stock by the CFO, even if for tax purposes, reduces his direct equity holding.

Future Outlook

The RSUs will vest in four equal annual installments following March 2, 2026, and the stock options will vest in 48 equal monthly installments following March 2, 2026, both subject to the CFO's continued employment.

Industry Context

StockSavvy.ai notes that equity grants to executive officers like a CFO are standard practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to align management incentives with long-term company performance and shareholder value creation. The use of Rule 10b5-1 plans for subsequent tax-related sales is also a common and prudent measure to avoid accusations of insider trading.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation practices in the biotech sector.
• Similar long-term incentive plans are observed at comparable companies such as Alnylam Pharmaceuticals (ALNY) or Sarepta Therapeutics (SRPT), where executive compensation often includes a significant equity component tied to performance and tenure.
• The specific grant amounts and vesting terms are generally benchmarked against peer groups to ensure competitive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's interests with long-term shareholder value. The tax-related sales are routine and unlikely to have a significant impact on share price or perception.
• Employees: The continued employment condition for vesting highlights the company's strategy to retain key talent.

Next Steps

• RSUs will vest in four equal annual installments following March 2, 2026.
• Stock options will vest in 48 equal monthly installments following March 2, 2026.
• Continued employment of the reporting person is required for vesting of both RSUs and stock options.

Key Dates

Recommendation

The filing details routine equity compensation and tax-related sales by a key executive under a pre-planned arrangement. While the equity grants are a positive sign of executive alignment, the sales are non-discretionary and do not signal a change in management's outlook. Therefore, the filing itself does not provide new information warranting a change in investment stance, suggesting a 'hold' recommendation based solely on this specific report.

Keywords

Kymera Therapeutics, KYMR, Bruce N. Jacobs, CFO, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Tax Withholding, Rule 10b5-1